Known scientifically as Synsepalum dulcificum, this fruit is commonly called the ‘miracle fruit’ because of its remarkable effect on taste buds — particularly for patients undergoing chemotherapy. CBS ...

Healthcare and pharmaceutical distributor McKesson Corporation is set to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, which does business as Core Ventures.

Almost a quarter of Florida’s residents who should be screened for this cancer aren't up-to-date with widely accepted ...

FORT MYERS, Fla., Feb. 26, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO (R) 2026 ...

NFL’s largest annual fundraiser announces milestone ahead of its signature run, walk and cycling event, DCC XVI, scheduled for Feb. 28, 2026.

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

This picture shows the tablets of Ivermectin drugs in Tehatta, West Benga, India on 19 May on 2021. Some Indian state governments have plans to dose their populations with the anti-parasitic drug ...

The National Cancer Institute, the federal research agency charged with leading the war against the nation’s second-largest killer, is studying ivermectin as a potential cancer treatment, according to ...

The Mayo Clinic in Jacksonville will begin proton and carbon ion cancer therapy starting next year. Florida is the first state to launch a carbon ion therapy program. Carbon ion therapy targets beams ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Local scientists work on ...

Patients are increasingly caught in disputes as health insurers and providers fail to agree on contract terms. A Florida cancer patient was forced to change his insurance plan to keep his doctors at a ...